Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Eisai said that the submissions are based primarily on data from a
Titan Pharma said that the Phase 3 study will be conducted at approximately 23 sites in the US and randomise approximately 250 patients into three arms: Probuphine (100
As per the terms of the agreement, AgaMatrix and sanofi-aventis are expected to co-develop solutions in diabetes management that incorporate AgaMatrix’s WaveSense technology. AgaMatrix’s proprietary WaveSense technology personalizes
BioNanomatrix has also disclosed the methods of preparing nanochannel array chips, methods of analyzing macromolecules such as entire strands of genomic DNA, and systems for implementing these methods.
Earlier, in September 2009, the World Health Organisation has entered into two sublicences, under its Global Pandemic Influenza Action Plan for developing countries, with the Government Pharmaceutical Organisation
As per the terms of the agreement, Bristol-Myers Squibb has agreed to pay NeurOp an upfront fee of $1.5m and to fund a two-year research collaboration. In addition,
Aildenafil is close in structure to Sildenafil and is expected to possess a similar pharmacological and adverse event profile. Sildenafil is the active pharmaceutical ingredient in an FDA-approved
Antisense therapies target the proteins involved in disease processes through the RNA that is involved in building these proteins. The Isis discovery platform develops specific therapies that bind
Duodart is indicated in the treatment of moderate-to-severe symptoms of benign prostatic hyperplasia (BPH) and reduction in the risk of acute urinary retention (AUR) and surgery in patients
AdvanDx said that the faster protocol reduces PNA Fish turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.